Fresenius Sells About 13.4 Million Shares, Cuts Stake to About 20%

Fresenius SE & Co. KGaA completed a sale of about 13.4 million shares in Fresenius Medical Care, raising about €524 million gross and reducing its investment in the separately listed company to about 20%.

The shares sold for €39 each, and Fresenius completed the transaction Nov. 12. Settlement is expected Nov. 16. The sale lowered Fresenius' financial investment from about 25% to about 20% of Fresenius Medical Care's issued share capital.

Fresenius plans to make the net proceeds available for investment in its growth platforms under its #FutureFresenius capital-allocation priorities. Its remaining shares are subject to a 90-day lock-up, with customary exceptions.

The reported stake of about 20% is calculated before any future exchanges of bonds into Fresenius Medical Care shares and cancellations under Fresenius Medical Care's current share buyback program.

Since Fresenius Medical Care's deconsolidation on Nov. 30, 2023, Fresenius has reduced its holding from about 32%, with cumulative gross proceeds of about €2.3 billion. The latest sale is expected to generate a book gain in the low- to mid-double-digit-million-euro range, which Fresenius plans to report as a special item in its fourth-quarter 2026 results.

“We are freeing up capital to invest in our growth platforms and pursue our strategic priorities in the REJUVENATE phase,” Fresenius Chief Financial Officer Sara Hennicken said.